The heatmap demonstrates that higher CD68/CD163 ratios were found to correlate with markers of disease progression and adverse clinical events, such as increased risk of thrombosis and progression to secondary myelofibrosis Supplementary Table 3. This evidence concerns the gene CD68 and myelofibrosis.